* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download pharm tech 2016-2017 class 2 ch 7 thru 13
Survey
Document related concepts
Orphan drug wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Pharmaceutical marketing wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Neuropharmacology wikipedia , lookup
Theralizumab wikipedia , lookup
Medical prescription wikipedia , lookup
Drug design wikipedia , lookup
Compounding wikipedia , lookup
Pharmacognosy wikipedia , lookup
Drug interaction wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Drug discovery wikipedia , lookup
Prescription costs wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Transcript
Ch 7: Requirements of the Pharmacy Area O State Laws Require Adequate Equipment and a Proper Environment for a Pharmacy to be Licensed O Proper location O Proper size O Must meet ADA requirements O Environmental conditions O Storage O Sterile compounding (if desired) O Hazardous waste storage/disposal © 2013-2015 Requirements of the Pharmacy Area (cont’d) O Security O Reference materials O Proper equipment O licensure © 2013-2015 Ch 8: How do we get a new drug? O Research O Investigation O Marketing © 2013-2015 The New Drug Approval Process O Put in place to protect the public O Steps insure that requirements of drug laws are met O Safety O Effectiveness O FDA is responsible for approval © 2013-2015 Mechanisms Involved O The New Drug Application (NDA) O The Investigational New Drug Review (INDA) © 2013-2015 The New Drug Application (NDA) O Used since the 1938 FDCA O Must prove both safety & effectiveness O Includes screening by several committees O Medical O Pharmacology O Chemistry O Statistical O Contains 4 Phases © 2013-2015 Phase 1 O Tests the maximum tolerated dose O Not designed to test efficacy O Uses a small subject group O Usually takes place at a single research facility © 2013-2015 Phase 2 O Determines the Effectiveness vs. Disease O Uses volunteers from the affected drug group O Usually several hundred subjects involved © 2013-2015 Phase 3 O Uses several thousand subjects O Multiple testing centers across the U.S. O “Double-Blind” Testing used O Neither the subject or the investigator know which is the active drug and which is placebo O Last phase before FDA consideration © 2013-2015 Phase 4 O Occurs AFTER FDA Approval and the drug is marketed O It is the responsibility of the practitioners using the drug to report adverse effects to the FDA O Many drugs have been removed from the market after negative Phase 4 reports. © 2013-2015 The Approval Process © 2013-2015 © 2013-2015 Drug Approval Facts O Average time to market runs 12 to 16 years O For every 5,000 drugs entering pre-clinical trials: O 5 will enter Phase 1 trials O 1 will gain FDA Approval © 2013-2015 Investigational New Drug Review (IND) O NOT an application for drug approval O IS an application for an exemption to the federal law prohibiting the interstate shipment of unapproved drug products O Usually occurs before NDA trials occur © 2013-2015 Drug Patents O Authority for patents comes from the U.S. Constitution O NOT the right to make a product O IS the right to forbid another from manufacturing the same product or importing it from another country O Period of 20 years, but begins from the time of application – Way before approval © 2013-2015 Ch 9: The Chemical Name O A description of the physical structure of the drug molecule O Gives information on: O How the molecule can be synthesized O How the molecule will react with other chemical compounds O How a drug will be metabolized O What actions the drug may have in the body © 2013-2015 The Generic Name O The name used for FDA approval on the NDA O Assigned by the manufacturer O Can give a clue as to the drugs actions O ie.) Suffixes -olol, -opril, -itidine, etc. O Used in communication between practitioners, in professional journals, and in research © 2013-2015 The Trade name O Used to build brand loyalty O Trademark O May also give a clue as to the advantages of a product O ie.) Lithobid - twice daily dosing O May have more than one trade name for a generic entity O ie.) Zestril vs. Prinivil © 2013-2015 The NDC Number O Used to identify the manufacturer, drug entity, and package size 00000-0000-00 00000-xxxx-xx Manufacturer xxxxx-0000-xx xxxxx-xxxx-00 Drug Entity Package © 2013-2015 Other Methods O Abbreviations - STUDY YOUR LIST O Mnemonic O Used in computer systems O No dependable commonality between systems © 2013-2015 Ch 10: Legal Classifications of Medicinal Products O Over the Counter O Legend O Controlled Substances O Schedule Listed Chemical Products © 2013-2015 Over the Counter O Determined to be safe for use without direct medical supervision O Must have complete instructions for use and warnings about misuse on every package © 2013-2015 Legend O Deemed too dangerous to use without direct medical supervision O Requires a prescription O Stock bottles must bear the legend warning © 2013-2015 Legend Warning © 2013-2015 Controlled Substances O Legend drugs which have a high potential for abuse – even with medical supervision O Special limitations on the prescription O Regulated by the 1970 Controlled Substances Act © 2013-2015 The “Closed System” of the Controlled Substances Act O Every facet of a drug’s manufacture, distribution, and use is tracked O A clear paper trail is generated O Requires licensing of practitioners who will handle controlled substances O The DEA Number © 2013-2015 The DEA Number O Unique identifying number for each person or entity who will have control over controlled substances O Issued by the Federal DEA O Who needs a DEA number? O Any practitioner who is registered by the State to prescribe, manufacture, or have possession of controlled substances O The State determines who needs, or can receive, a DEA number © 2013-2015 The DEA Number is “Self Verifying” O All the information needed to check the validity of the number, is contained within the number itself O All DEA numbers start with a letter O All DEA numbers have the first initial of the practitioner’s last name as their 2nd digit O Then Seven Numbers © 2013-2015 To Verify a DEA Number Example: AA0242622 O Add the 1st, 3rd, and 5th numbers 0 + 4 + 6 = 10 O Add the 2nd, 4th, and 6th numbers then double the sum 2 + 2 + 2 = 6 x 2 = 12 O Add the two answers together 10 + 12 = 22 O The resulting sum should have a digit that matches the last digit of the DEA number © 2013-2015 The “Schedules” O Schedule I O Schedule II O Schedule III O Schedule IV O Schedule V Know common drugs in each schedule! © 2013-2015 Bottle Labeling for Controls A large letter “C” and the number of the schedule to which the product belongs © 2013-2015 The Warning “Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed” **Must appear on every controlled substance prescription dispensed © 2013-2015 SLCP Classification O Schedule Listed Chemical Products (SLCP) O Created by The Combat Methamphetamine Epidemic Act of 2005 (CMEA) O Pseudoephedrine O Requirements for keeping SLCP’s behind the pharmacy counter O MUST be dispensed by a licensed pharmacist O Quantity limits O Must be at least 18 years old © 2013-2015 Ch 11: Routes of Administration O Route of Administration = How a Drug Enters the Body O Parenteral vs. Enteral O Common Routes of Administration O Know what each route is, and its abbreviation! © 2013-2015 Parenteral vs. Enteral O Enteral Administration occurs any time the drug is introduced at any point along the “tube” which runs from the mouth to the anus O Parenteral Administration covers any other entry besides topical. O Topical Administration occurs when the drug is applied to the outside surface of the body. Absorption into the body may, or may not take place. © 2013-2015 Common Routes of Administration O PO - By mouth O NG - Naso-Gastic O SL - Sublingual O BUCCAL - between the cheek & gum O IV bolus – volume of fluid delivered over a short period of time O IV drip – volume of fluid delivered over a long period of time O IV piggyback - small volume of fluid delivered thru the tubing of another IV © 2013-2015 Routes (cont’d) O IM - Intra-muscular O SC (SQ, subcut) - Subcutaneous O IC - Intracardiac O Transdermal - Through the skin O Topical - Applied externally Memorize these abbreviations! © 2013-2015 Dosage Forms O Solids O Liquids O Semi-Solids © 2013-2015 Solid Dosage Forms O Tablets O O O O Compressed Enteric Coated Sustained Release Sublingual / Buccal O Capsules O May also be sustained release O Good choice for bad tasting medications © 2013-2015 Liquid Dosage Forms O Solution O drug is dissolved in diluent O Suspension O small particles are suspended in a liquid O Syrup O sweetened vehicle O Elixir O vehicle contains a high percentage of alcohol O Extract O drug is the oil or active portion of a plant O Tincture O alcohol based dosage form used externally © 2013-2015 Semi-Solid Dosage Forms O Cream O Actually an Emulsion. Active ingredients are dissolved in oil droplets and suspended in water. O May be “broken” excess heat or cold O Lotion O A thinner emulsion than a cream O Ointment O generally petrolatum based O won’t absorb into skin like emulsions O more potent on a gram per gram basis © 2013-2015 Ch 12: Patient Confidentiality O Every patient has the right to expect confidentiality O We must protect patient information and be aware of any unintended transfer of information O Elevators O Corridors O Lunch Room O Telephone Conversations O Never allow yourself to be overheard when speaking about patient specific information © 2013-2015 The HIPAA Law O Health Insurance Portability and Accountability Act of 1996 O Took effect in 2003 O Formalized confidentiality policies O Affects health care providers, health insurance companies, and health care payment companies © 2013-2015 The HIPAA Law O Administered by the US Department of Health and Human Services O Enforced by the Office of Civil Rights O Controls access to a patient’s Protected Health Information (PHI) © 2013-2015 The Notice of Privacy Practices O Must be given to every patient or their guardian O Explains how the pharmacy will use their PHI O Explains the patient’s rights regarding their own PHI O Best to have the patient sign a log to prove they received the Notice © 2013-2015 Release of PHI Under the HIPAA Law: O We MUST release PHI when: O the patient requests their own information O the HHS Office of Civil Rights requests PHI O We MAY release PHI when it involves: O the patient’s treatment O the payment for treatment O the day to day operation of the pharmacy O These reasons MUST be listed on the Notice of Privacy Practices © 2013-2015 HIPAA Exemptions O The HIPAA Law specifically exempts three organizations from its restrictions: O law enforcement agencies O Food & Drug Administration O worker’s compensation claims © 2013-2015 Patient Rights on PHI O Patients have the right to: O restrict the release of their PHI O amend their PHI O request an accounting of who has viewed their PHI O request confidential communications © 2013-2015 Management of HIPAA O Each pharmacy organization must appoint a HIPAA Compliance Officer who is the final judge on all HIPAA decisions O All HIPAA documentation must be retained for 6 years O HIPPA affects various practice settings O Technicians may encounter problems © 2013-2015 The HITECH Act O Updates HIPPA O Takes into account the increase use of computers and transmission of electronic devices O Greatly increases punishment for unauthorized release of PHI O Important provisions: O Strengthens electronic security of PHI O Allows online access to PHI by patient O Allows online submission of PHI forms O Regulates the patient notification of PHI breaches O Clarifies the definitions of who may access PHI and under what circumstances © 2013-2015 The HITECH Act (cont.) O Understand that: O Penalties, including criminal and financial, may now be leveled against any individual member of the pharmacy team that is held responsible! O Updated HIPPA requirements are contained in a table in Chapter 12 © 2013-2015 Reasons Not to Use a Drug O Any lack of confidence in the product O Inappropriate storage conditions O Questionable source O Different appearance than normal O Many counterfeit drugs O Verify any changes in product labeling or appearance O Questionable equivalence © 2013-2015 Reasons to Contact a Prescriber O Any time there is a question about clarity, intent, or safety O Contact the prescriber BEFORE you fill the order! © 2013-2015 Reasons to Refuse a Prescription O When a legitimate medical reason for the prescription does not exist O When the pharmacist determines the filling of the order will be harmful to the patient and the problem can not be resolved with the prescriber O When the sole reason for the prescription is to support a drug addiction O The DEA has stated that this is not a valid reason for a prescription O Except a licensed drug addiction treatment center © 2013-2015 Illegitimate and Fraudulent Prescriptions O It is important that we are aware of attempts to illegally obtain prescription drugs O Always bring questionable prescriptions to the pharmacist’s attention O A prescription may not be legitimate if: O Being prescribed for an indication that is not approved O One particular provider writing abnormally high numbers of prescriptions or quantities O Large number of individuals dropping off prescriptions in someone else’s name O Large increases in controlled substance orders being © 2013-2015 generated by your pharmacy Illegitimate and Fraudulent Prescriptions O Indications that a prescription may be forged: O Looks too good O Quantities, directions, or dosages that vary from the norms O Photocopied prescription blanks O Different colored ink used on the same prescription blank O Erasures or changes on the prescriptions © 2013-2015 Drug Use in Pregnancy O Know the categories that are safe, and unsafe, for use in pregnancy O The FDA assigns pregnancy categories to medications according to their known risks O Study Chart in Chapter 12 © 2013-2015 Ch 13: The OBRA Law O Omnibus Budget Reconciliation Act (1990) O The purpose of OBRA was to capture potential cost savings in the Medicaid drug program How? Get pharmacists involved in drug therapy © 2013-2015 How OBRA Saves Money O Retrospective Drug Utilization Review O Education of Practitioners O Prospective Drug Utilization Review O Patient Counseling O Rebates from Manufacturers © 2013-2015 Retrospective DUR O Happens AFTER the drug is dispensed O Identify inappropriate use of drugs O Watches prescribing habits of practitioners O Generates FUTURE savings O Solves FUTURE problems © 2013-2015 Education of Practitioners O OBRA makes the State Board of Pharmacy responsible for educating practitioners about the findings of the retrospective DURs O Keeps practitioners current with recommended prescribing method © 2013-2015 Prospective DUR O Occurs BEFORE the drug is dispensed O Done by the pharmacist who dispenses the medication O Only step which catches problems BEFORE they occur O Phases of the prospective DUR O The error can be corrected BEFORE the patient receives the medication © 2013-2015 Prospective DUR Review O Drug duplication? O Drug / Disease contraindication? O Drug / Drug interaction? O Incorrect dosing or duration? O Drug allergies? O Clinical abuse or misuse? © 2013-2015 Patient Counseling O OBRA mandates we offer to counsel EVERY Medicaid patient O Most states have expanded OBRA to include every patient O Notice, we offer, but the patient can refuse O If the patient accepts counseling, the PHARMACIST must provide it © 2013-2015 Patient Counseling Should Include O O O O O O O O O Medication name & description Dosage route & duration Special directions or precautions Common side effects Therapeutic contraindications Required self monitoring Proper storage Refill information Missed dose information © 2013-2015 Questions? © 2013-2015 Assignments Due Next Week O Class Two Homework Worksheet O Study Drug Flash Cards # 21 – 40 NEXT WEEK IS OUR FIRST SECTION TEST! Covers Chapters 1 thru 13 NO MATH QUESTIONS © 2013-2015